NCT05324410View on ClinicalTrials.gov

A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

April 7, 2022

Primary Completion Date

November 7, 2022

Study Completion Date

November 7, 2022

Conditions
APOL1-mediated Kidney Disease
Interventions
DRUG

VX-840

Solution for oral administration.

DRUG

Placebo

Placebo matched to VX-840 for oral administration.

Trial Locations (1)

66219

ICON Lenexa, Lenexa

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY